Clinical Trial Update: Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating eflornithine to prevent skin cancer in patients with previously treated non-melanomatous skin cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-melanomatous Skin Cancer

Drugs mentioned

• Eflornithine (eflornithine)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Non-melanomatous Skin Cancer | Phase 3 | Status: COMPLETED